Condensed Consolidated Statements of Stockholders’ Equity (Deficit) - USD ($) $ in Thousands |
Total |
February 2026 P I P E Transaction |
May 2025 P I P E Transaction |
May 2025 P I P E Transaction
Series B Warrants
|
Common Stock |
Common Stock
May 2025 P I P E Transaction
|
Common Stock
May 2025 P I P E Transaction
Series B Warrants
|
Additional Paid-In Capital |
Additional Paid-In Capital
February 2026 P I P E Transaction
|
Additional Paid-In Capital
May 2025 P I P E Transaction
Series B Warrants
|
Accumulated Other Comprehensive Income |
Accumulated Deficit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beginning balance (in shares) at Dec. 31, 2024 | 9,015,087 | |||||||||||
| Beginning balance at Dec. 31, 2024 | $ 18,429 | $ 8 | $ 525,611 | $ 4,209 | $ (511,399) | |||||||
| Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||||
| Net loss | (25,473) | (25,473) | ||||||||||
| Stock-based compensation | 2,042 | 2,042 | ||||||||||
| Foreign exchange translation adjustment | (285) | (285) | ||||||||||
| Ending balance (in shares) at Mar. 31, 2025 | 9,015,087 | |||||||||||
| Ending balance at Mar. 31, 2025 | $ (5,287) | $ 8 | 527,653 | 3,924 | (536,872) | |||||||
| Beginning balance (in shares) at Dec. 31, 2025 | 12,038,263 | 12,038,263 | ||||||||||
| Beginning balance at Dec. 31, 2025 | $ (6,673) | $ 9 | 599,241 | 2,648 | (608,571) | |||||||
| Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||||
| Net loss | (32,588) | (32,588) | ||||||||||
| Stock-based compensation | 1,443 | 1,443 | ||||||||||
| Foreign exchange translation adjustment | $ 409 | 409 | ||||||||||
| Issuance of common stock | $ 187,263 | $ 187,263 | ||||||||||
| Exercise of warrants (in shares) | 1,383,220 | 1,383,220 | 200,000 | |||||||||
| Exercise of warrants | $ 2 | $ 1,377 | $ 2 | $ 1,377 | ||||||||
| Ending balance (in shares) at Mar. 31, 2026 | 13,621,483 | 13,621,483 | ||||||||||
| Ending balance at Mar. 31, 2026 | $ 151,233 | $ 11 | $ 789,324 | $ 3,057 | $ (641,159) |
| X | ||||||||||
- Definition Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. No definition available.
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of shares issued during the period as a result of the conversion of convertible securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The gross value of stock issued during the period upon the conversion of convertible securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|